FILE - This Tuesday, April 3, 2018 file photo shows a closeup of a beam scale in New York. One of the most popular weight loss drugs on the market could soon be covered under more insurance plans.
Wegovy maker Novo Nordisk said its product could receive expanded approval rom the U.S. Food and Drug Administration within six months,The company has received a priority review from the FDA for the use of Wegovy as a treatment for reducing the risk of cardiovascular disease. If approved, the change could expand prospects for insurance coverage for the drug, which has, so far, been approved only for weight loss.
CNBC reported data from August showed Wegovy reduced the risk of major cardiovascular events such as heart attacks or stroke by 20% when compared to a placebo.If you purchase a product or register for an account through a link on our site, we may receive compensation.